SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary quarterly update sharply raised its revenue and gross-margin outlook on stronger AI-platform demand, driving a major after-hours rally. Many traders welcomed the improved outlook and anticipated further gains or short covering, while others questioned whether the momentum would hold given the companys volatile history and lingering trust concerns.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results beat expectations, with rapid growth in its AI compute business and an aggressive buildout outlook driving strong enthusiasm. Traders are also debating whether the ambitious growth targets justify the valuation given heavy capital spending and uncertain execution.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly profit beat expectations, but softer forward guidance and a reduced advertising-revenue outlook have intensified concerns about slowing growth and weighed on the shares. Traders are debating whether the ad business and content strategy can revive momentum, with many bearish while some view the selloff as overdone and are buying the dip.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

A sharp, high-volume rebound has put WULF in focus, with traders crediting CEO Paul Pragers CNBC interview and his explanation of the companys powered-shell model: leasing data-center infrastructure and power rather than buying GPUs. Bulls see its AI/HPC contracts and buildout as differentiating it from debt-heavy neocloud peers, while skeptics call the move a relief bounce and remain concerned about financing, execution, and the broader sector selloff.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports RAP-219 Phase 2 trial in acute bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential beyond epilepsy. Traders are split: some view the results as validation of the pipeline, while others cite the modest placebo-adjusted benefit and higher agitation-related discontinuations as reasons for caution as the early gains faded.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCN is drawing attention amid a price rebound and breakout chatter, with bullish traders pointing to Zebecs reported payroll, card and network adoption, including its Stellar deployment. Skeptics counter that the token has struggled to sustain gains and say adoption must translate into stronger usage, volume and token demand.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Anticipation of Reddits upcoming quarterly results is driving discussion, with traders watching for evidence that ad growth and AI data licensing can support the stock. Bulls expect strong results to break its recent range, while bears point to insider selling, valuation concerns, and frustrating price action.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Middle East shipping and infrastructure threats that raise fears of oil-supply disruptions. Bulls see the geopolitical risk premium supporting crude, while bears expect it to unwind if shipping flows normalize or peace talks progress, fueling debate over the funds volatile moves.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgicals strong Q3 earnings beat was met with a sharp selloff, as traders focused on the narrowed da Vinci procedure-growth outlook and planned pricing cuts that could pressure revenue per procedure. The community is split between calling the reaction an overdone sell-the-news move and viewing slower growth and the litigation settlement as reasons for caution.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention for outperforming the cap-weighted S&P 500 as gains spread across more constituent stocks while mega-cap technology lagged. Traders view the strength as evidence of broader participation and rotation beyond tech, though some caution that the improvement may not last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Shares Of SeaStar Medical Today?

Shares of SeaStar Medical Holding Corporation (NASDAQ: ICU) are trading lower Friday after the company initiated a reverse stock split.read more...

A Glimpse of SeaStar Medical Holding's Earnings Potential

SeaStar Medical Stock Jumps On Safety Board Backing For Kidney Trial; Retail Eyes Another Run Despite After-Hours Plunge

Equity

The trial’s enrollment target has been raised to 339 patients, with completion expected by late 2026.

SeaStar Medical Stock Tanks At Discounted Pricing Of Public Offering, Retail Believes Company Is Inching Closer To Bankruptcy

The public offer price of $0.65 represents a 33% discount on the stock’s closing price on Wednesday.

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

SeaStar Medical Holding Corp

Bearish Sentiment

SeaStar Medical Holding Corp. shares rose 7% to their highest level in more than three months on Wednesday after the company said an independent safety board had reviewed early data and recommended continuing its pivotal trial of a kidney failure therapy.However, the stock&nbsp;crashed 46% in after-hours trading on Wednesday.The Data Safety Monitoring Board (DSMB) conducted an interim review of the first 100 patients in the Neutralize-AKI study of the company’s Selective Cytopheretic Device (SCD) in adults with acute kidney injury requiring continuous renal replacement therapy.&nbsp;The panel found no device-related safety concerns and reported zero adverse events tied to the treatment. It also flagged a signal of potential clinical benefit across key measures.To boost the statistical power of the trial, the DSMB recommended increasing enrollment from 200 to 339 patients. SeaStar said 137 patients have already been enrolled and expects to complete recruitment near the end of 2026. The company plans to accelerate enrollment by adding new trial sites.The Neutralize-AKI trial will measure a composite of 90-day mortality or dialysis dependency, with additional endpoints including 28-day mortality, ICU-free days, and dialysis dependency at one year. Subgroup analyses will evaluate patients with sepsis and acute respiratory distress syndrome.SeaStar’s SCD therapy, marketed as Quelimmune, is already approved by the FDA for life-threatening acute kidney injury in children with sepsis or septic conditions. Early real-world registry data showed no safety concerns and a 75% survival rate at 28 days, suggesting a possible reduction in mortality compared with historical outcomes.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested that warrant holders had timed the news to capitalize on the stock’s spike, noting they could profit as long as shares remained above their average price and questioning whether the market could absorb the additional supply.<stembedurl>https://stocktwits.com/alphaonetrading/message/629922155</stembedurl>Another user said the recent price surge was only the beginning, arguing that strong safety signals from the trial support future runs and calling any near-term pullback a buying opportunity for the long term.<stembedurl>https://stocktwits.com/MasheredTrader/message/629918153</stembedurl><a href="https://stocktwits.com/symbol/ICU">SeaStar Medical’s stock</a> has declined 36.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

SeaStar’s SCD therapy, marketed as Quelimmune, is already approved by the FDA for life-threatening acute kidney injury in children with sepsis or septic conditions.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.05
Prev Close	$3.11
Open	$3.11
Dividend Yield	0.00%
50-Day Moving Average	$3.32
Beta	0.61
Avg. Volume	45,449.81
PE Ratio	-0.78

52-Week High	$6.48
52-Week Low	$2.07
Market Capitalization	$13.71M
EPS (Annual)	-$5.86
Price to Book	3.02
Revenue Per Employee	$72,588.24

Feed

News

Sentiment

Fundamentals

Info

ICU Fundamentals